Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL
Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Mary Ann Anderson(The Royal Melbourne Hospital), Evangelia Minga(Centre for Research and Technology Hellas), Persefoni Talimtzi(Centre for Research and Technology Hellas), Enrica Antonia Martino(Ospedale Annunziata di Cosenza), Massimo Gentile(Azienda Ospedaliera di Cosenza), Ιoannis Kotsianidis(Democritus University of Thrace), María José Mela Osorio(Universidad de Buenos Aires), Ewa Wąsik‐Szczepanek(Medical University of Lublin), Juan Marquet(Instituto Cajal), Blanca Ferrer Lores(Hospital Clínico Universitario de Valencia), Alessandro Cellini(University of Padua), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Christian Brieghel(Copenhagen University Hospital), Eugene Nikitin(Botkin Hospital), Lydia Scarfò(IRCCS Ospedale San Raffaele), Celso Arrais‐Rodrigues(Hotel Dieu Hospital), Anastasia Chatzidimitriou(Karolinska Institutet), Münci Yağcı(Gazi University), Pär Josefsson(Copenhagen University Hospital), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Visentin(University of Padua), Michael Doubek(Central European Institute of Technology), Blanca Espinet(Hospital Del Mar), Maria Kislova(Botkin Hospital), Verena Pfister(Federal Institute of São Paulo), Sotiria Dimou‐Besikli(Centre for Research and Technology Hellas), Enrico Lista(Arcispedale Sant'Anna), Emine Merve Savaş(Gazi University), Mariia Mikhaleva(Dana-Farber Cancer Institute), Niki Stavroyianni(G. Papanikolaou General Hospital), Amalia Cerutti(Hospital Británico), Paula Jabłonowska-Babij(Wroclaw Medical University), Martin Šimkovič(Charles University), Ozren Jakšić(University of Zagreb), Antigoni Tranidou(Aristotle University of Thessaloniki), Elżbieta Kalicińska(The University of Melbourne), José A. García-Vela(Hospital Universitario Puerta de Hierro Majadahonda), Lev Shvidel(Kaplan Medical Center), Lisbeth Enggaard(Copenhagen University Hospital), Tomasz Wróbel(Wroclaw Medical University), Matjaž Sever(University of Ljubljana), Yair Herishanu(Tel Aviv University), Christina Papangelou(Centre for Research and Technology Hellas), Eva Gimeno Vázquez(Hospital Del Mar), Ciaran P McAuley(The Royal Melbourne Hospital), Miguel Arturo Pavlovsky(Universidad de Buenos Aires), Claudia Mosquera Rubal(Azienda Ospedaliera di Cosenza), Odit Gutwein(Assaf Harofeh Medical Center)
Cited by 2
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752